Prelude Therapeutics: Jumps 33% in Nasdaq debut

Prelude Therapeutics Incorporated

25/09/2020 17:02

** Prelude Therapeutics Inc's shares  PRLD.O  jump ~33% to 
$25.23 in their market debut, valuing the cancer biotech co at
$1.71 bln
    ** Co raised $158.2 mln in its IPO after pricing 8.3 mln
shares at the top end of its target range of $17-$19
 urn:newsml:reuters.com:*:nGNX68H5y1
    ** The company plans to use the proceeds, along with its
cash in hand, to advance the clinical development of the
products in its pipeline 
    ** Morgan Stanley, Goldman Sachs & Co. and BofA Securities
are acting as joint book-running managers for the offering

 (Reporting by C Nivedita and Abhishek Manikandan in Bengaluru)
 ((C.nivedita@thomsonreuters.com))